Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
U.S. Senator Elizabeth Warren has sent a letter to the nation's leading patent attorney asking for further review of Merck's new patent application for its cancer drug Keytruda, which seeks to block the drug. , he said.
Read Full NewsIn children with difficult-to-treat glaucoma, a nonvalved implant yields sustained reductions in intraocular pressure and medication burden for up to 5 years.
A population-based study finds that children with spina bifida are more likely than their peers in the general population to develop chronic kidney disease and ESRD — and to do so at younger ages.
1.
Mental health risk persists years after cancer diagnosis
2.
In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.
3.
Breast Cancer Patients Living Longer Post-Medicaid Expansion
4.
Fear of hair loss might cause some to reject cancer treatment
5.
Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer
1.
Harnessing Cuproptosis: A Novel Nanomedicine Strategy for Triple-Negative Breast Cancer
2.
Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy
3.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
4.
Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights
5.
Obesity as a major risk factor for cancer
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part XV
2.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Thromboprophylaxis In Medical Settings- An Update
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge